W
Wenyu Zhu
Researcher at Incyte
Publications - 43
Citations - 1203
Wenyu Zhu is an academic researcher from Incyte. The author has contributed to research in topics: Janus kinase & Cancer. The author has an hindex of 15, co-authored 40 publications receiving 1126 citations.
Papers
More filters
Journal ArticleDOI
INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology
Eddy W. Yue,Richard B. Sparks,Padmaja Polam,Dilip P. Modi,Brent Douty,Brian Wayland,Brian M. Glass,Amy Takvorian,Joseph Glenn,Wenyu Zhu,Michael J. Bower,Xiangdong Liu,Lynn Leffet,Qian Wang,Kevin Bowman,Michael Hansbury,Min Wei,Yanlong Li,Richard Wynn,Timothy Burn,Holly Koblish,Jordan S. Fridman,Tom Emm,Peggy Scherle,Brian Metcalf,Andrew P. Combs +25 more
TL;DR: In vitro ADME data is consistent with the good cell permeability and oral bioavailability observed in all species (rat, dog, monkey) tested and the extensive intramolecular hydrogen bonding observed in the small molecule crystal structure of 4f is believed to significantly contribute to the observed permeable and PK.
Patent
1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3-Dioxygenase
Andrew P. Combs,Eddy W. Yue,Sparks Richard B,Wenyu Zhu,Jiacheng Zhou,Qiyan Lin,Lingkai Weng,Yue Tai-Yuen,Pingli Liu +8 more
TL;DR: In this article, the present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders.
Journal ArticleDOI
Structure-based design and discovery of protein tyrosine phosphatase inhibitors incorporating novel isothiazolidinone heterocyclic phosphotyrosine mimetics.
Andrew P. Combs,Eddy W. Yue,Michael J. Bower,Paul J. Ala,Brian Wayland,Brent Douty,Amy Takvorian,Padmaja Polam,Zelda Wasserman,Wenyu Zhu,Matthew L. Crawley,James Russell Pruitt,Richard B. Sparks,Brian M. Glass,Dilip P. Modi,Erin McLaughlin,Lori L. Bostrom,Mei Li,Laurine G. Galya,Karl F Blom,Milton Hillman,Lucie Gonneville,Brian Reid,Min Wei,Mary Becker-Pasha,Ronald M. Klabe,Reid Huber,Yanlong Li,Gregory Hollis,Timothy Burn,Richard Wynn,Phillip Liu,Brian Metcalf +32 more
TL;DR: The crystal structure of PTP1B in complex with the most potent inhibitor 12 revealed that the (S)-IZD heterocycle interacts extensively with the phosphate binding loop precisely as designed in silico.
Journal ArticleDOI
Potent benzimidazole sulfonamide protein tyrosine phosphatase 1B inhibitors containing the heterocyclic (S)-isothiazolidinone phosphotyrosine mimetic.
Andrew P. Combs,Wenyu Zhu,Matthew L. Crawley,Brian M. Glass,Padmaja Polam,Richard B. Sparks,Dilip P. Modi,Amy Takvorian,Erin McLaughlin,Eddy W. Yue,Zelda Wasserman,Michael J. Bower,Min Wei,Mark Rupar,Paul J. Ala,Brian M Reid,Dawn Ellis,Lucie Gonneville,Thomas Emm,Nancy Taylor,Swamy Yeleswaram,Yanlong Li,Richard Wynn,Timothy Burn,Gregory Hollis,Phillip Liu,Brian Metcalf +26 more
TL;DR: The ortho substitution to the (S)-IZD on the aryl ring afforded low nanomolar enzyme inhibitors of PTP1B that also displayed low caco-2 permeability and cellular activity in an insulin receptor (IR) phosphorylation assay and an Akt phosphorylated assay.
Patent
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
TL;DR: In this article, the present invention provides cyclobutyl substituted pyrrolopyrimidines (PPRD) and pyrroleopyridines of Formula I: X, Y, Z, L, A, R5, n and m are defined above, as well as their compositions and methods of use, that modulate the activity of Janus kinases.